Quarterly report · Q2
4543.TEDINET S100PLTQ
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥403.3bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥206.0bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥703.3bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥344.6bn | 2021-04-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥172.9bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥56.0bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥25.5bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥65.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥29.6bn | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥54.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥25.0bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥114.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥65.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥29.3bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥40.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥17.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥88.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥50.0bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥22.1bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥40.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥17.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥50.0bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥22.1bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥1.66T | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.47T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.37T | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥487.8bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥461.4bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.17T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥904.0bn | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥856.7bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.17T | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.01T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥904.0bn | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥212.6bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥202.9bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥200.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥60.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥141.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥66.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥31.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥78.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥40.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥37.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥70.9bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥25.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥53.37 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.75 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥117.45 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥66.11 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥29.22 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥53.35 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.74 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥117.38 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥66.07 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥29.2 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 70.6% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.7% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 66.0% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥124m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥275m |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥74.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥9.1bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥235.4bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥52.9bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥93.8bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥8.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥403.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥70.2bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-09-30 | ¥124m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥58.2bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥11.8bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥194.3bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥50.8bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥92.0bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥13.4bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥344.5bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥76.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 696
| Item | Context | Value | Unit |
|---|---|---|---|
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -4146000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReportableSegmentsMember | -7769000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReconcilingItemsMember | -144000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration | -7913000000 | JPY |
| Non recurring profit or loss IFRS | Prior1YTDDuration | -366000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 65857000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 439000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 1342000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 326000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 65282000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 235405000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 93805000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 73980000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 403191000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | 124000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 403316000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 52905000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 8147000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 9102000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 70154000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | 275000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration | 70429000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -4446000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -5060000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_ReportableSegmentsMember | -9506000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_ReconcilingItemsMember | -11000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration | -9518000000 | JPY |
| Non recurring profit or loss IFRS | CurrentYTDDuration | -4934000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 55977000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 929000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 1978000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration | -303000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 54624000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第108期第２四半期(自 2022年７月１日 至 2022年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)テルモ株式会社 | |
| Company name in english cover page | FilingDateInstant | TERUMO CORPORATION | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長CEO 佐藤 慎次郎 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区幡ケ谷二丁目44番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03(3374)8111(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Text · Plus | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都新宿区西新宿三丁目20番２号 東京オペラシティタワー 49F | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03(6742)8500(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Text · Plus | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E01630 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |